logo
  

Bayer's Finerenone Meets Primary Endpoint In Phase III FIDELIO-DKD Renal Outcomes Study

Bayer (BAYZF.PK,BAYRY.PK,BYR.L) announced that the Phase III study FIDELIO-DKD, which is evaluating the efficacy and safety of finerenone versus placebo when added to standard of care for chronic kidney disease or CKD in patients with type 2 diabetes or T2D, has met its primary endpoint.

The results show that the investigational drug finerenone delayed the progression of CKD by reducing the combined risk of time to first occurrence of kidney failure, a sustained decrease of estimated glomerular filtration rate or eGFR greater than or equal to 40% from baseline over a period of at least four weeks, or renal death.

Finerenone also reduced the risk of the key secondary endpoint, a composite of time to first occurrence of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, or heart failure hospitalization.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Sturtevant, Wisconsin-based BRP U.S. Inc. is recalling around 20 models of Side-by-Side vehicles citing fire risk, the U.S. Consumer Product Safety Commission. The recall involves about 34,400 units of Model Years 2020 and 2021 Can-AM Defender HD10 side-by-side vehicles. While reporting financial results for the second quarter on Friday, technology company Honeywell international Inc. (HON) raised its adjusted earnings and sales guidance for the full-year 2021, based on the second-quarter performance and management's outlook for the remainder of the year. For fiscal... Shares of Vodafone Group Plc were gaining around 2 percent in the morning trading in London after the British telecom major reported higher revenues in its first quarter. Looking ahead, the company said it is on track to deliver fiscal year 2022 guidance, with Adjusted EBITDAaL expected to be between 15.0 billion euros - 15.4 billion euros and Adjusted free cash flow of at least 5.2 billion euros
Follow RTT